News

New Publication Announcement in Partnership with Stanford Sleep Medicine and UCSF

September 18, 2025

We at Fullpower-AI® are proud to share our latest peer-reviewed study, published in the Journal of Sleep Medicine: https://doi.org/10.1016/j.sleep.2025.106808


This large-scale U.S. study evaluates home-based, under-mattress devices (the Sleeptracker-AI® platform) for the detection and prevalence of Obstructive Sleep Apnea (OSA) — comparing its accuracy to traditional in-lab polysomnography (PSG).

Key Findings

High Accuracy: Sleeptracker-AI reliably detects moderate to severe OSA, with results comparable to gold-standard lab tests.

Consistency: Strong night-to-night reliability supports continuous monitoring.

Clinical Relevance: Expansion into telemedicine programs can expand early screening and management of OSA.

Why It Matters

Comfort & Accessibility: Patients can be screened at home, increasing adherence and reducing barriers to care.

Cost & Efficiency: Faster, more scalable diagnostics lower healthcare costs and shorten wait times.

Equity & Reach: Brings sleep health to underserved and remote populations.

This work reinforces the transformative role of the Sleeptracker-AI, a non-invasive, continuous, home-based biosensing platform, in improving the early detection and management of sleep-disordered breathing.

At Fullpower-AI, we are committed to advancing science-backed, AI-powered solutions that improve health outcomes worldwide.

Fullpower-AI

About Fullpower-AI®
Fullpower-AI® empowers companies to unlock and maximize actionable insights in real-time, turning them into real-world actions.

Our flagship platforms, KOA and Sleeptracker-AI®, continuously process vast streams of biosensing and application-relevant data. By applying advanced data science, predictive AI, and specialized large action-focused generative AI, we aggregate diverse streams of data, analyze into precise, actionable intelligence, and act through connected devices to take real-world actions that drive optimal outcomes. Stanford Medicine and UCSF independently vet our platform.